We report the final 3-year efficacy and safety outcomes from a trial of outpatient administration of brentuximab vedotin (BV) plus bendamustine as a first salvage regimen in relapsed/refractory Hodgkin lymphoma (HL).
In this phase 1/2, open-label, single-arm study, 55 adult patients with relapsed or refractory HL received outpatient intravenous infusions of BV 1Á8 mg/kg on Day 1 and bendustamine 90 mg/m 2 on Days 1 and 2 of 3-week cycles for up to six cycles, followed by autologous stem cell transplantation (ASCT) and/or BV monotherapy for up to 16 cycles. Patients underwent computed tomography every 3 months for the first year and every 6 months thereafter until study closure, which occurred approximately 3 years after the last patient's ASCT. Treatment response was assessed with the 2007 Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007) . Of 53 efficacy evaluable patients, 40 (75Á5%) underwent ASCT and 13 (24Á5%) did not. Of 25 patients who underwent ASCT and six who did not continue BV monotherapy; 17 patients completed the maximum allowed 16 cycles of BV monotherapy. We previously reported 2-year outcomes, including a 92Á5% objective response rate (ORR), a 73Á6% complete remission (CR) rate, and estimated 2-year progression-free survival (PFS) of 62Á6% overall and 69Á8% for those who received ASCT (LaCasce et al., 2018) . As reported, the regimen was generally well tolerated; notable adverse events included infusion-related reactions (largely manageable with premedication) in 56Á4% of patients and peripheral neuropathy (PN) in 54Á4% of patients, including 16Á4% Grade 2, 3Á6% Grade 3, and no Grade 4 or 5 PN events (LaCasce et al., 2018) .
The median (range) follow-up for the final overall survival (OS) evaluation was 44Á5 (4-55) months from first dose and 41Á8 (0-52) months from ASCT ( Fig 1A) . OS at 3 years was 92Á0% [95% confidence interval (CI) 80Á0-96Á9%] with no difference between patients who did and did not undergo ASCT. Five patients died (none considered treatment-related), including three deaths reported previously (LaCasce et al., 2018), and two additional deaths in patients with disease progression after ASCT (one related to progressive HL and one of unknown cause). The median (range) follow-up for PFS evaluation was 38Á7 (1-53) months from first dose and 36Á6 (0-51) months from ASCT ( Fig 1B) . PFS at 3 years was 60Á3% (95% CI 43Á5-73Á6%) overall, 67Á1% (95% CI 47Á9-80Á5%) for patients who went on to ASCT, and 40Á4% (95% CI 12Á5-67Á4%) for patients who did not undergo ASCT. A total of 19 PFS events (18 disease progressions and one death) occurred, including 17 events that were reported previously (LaCasce et al., 2018) and subsequent progressive disease reported in one patient who had undergone ASCT and one who had not. In all, 13 of 15 patients with >3 years of follow-up were progression-free at the last follow-up. Duration of CR was similar among patients who did and did not undergo ASCT ( Fig 1C) .
These OS and PFS results with BV-bendamustine as first salvage therapy compare favourably with 2-4-year follow-up data reported for other pre-ASCT salvage regimens in relapsed/refractory HL. Among patients treated with bendamustine-gemcitabine-vinorelbine (BeGEV) before ASCT, the overall 2-year OS was 77Á6% and 2-year PFS rates of 62Á2% overall and 80Á8% for transplanted patients were reported (Santoro et al., 2016) . The 2year OS and PFS were 88% and 46%, respectively, among patients treated with ofatumumab in combination with etoposide, steroids, cytarabine and cisplatin (O-ESHAP), most (80%) of whom underwent subsequent ASCT (Martinez et al., 2016) . In a study of pre-ASCT augmented ifosfamide, carboplatin, and etoposide (ICE) followed by gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) for non-CR patients, 4-year OS was 80% and 4-year event-free survival rates of 70% overall and 79% for transplanted patients were reported .
Peripheral neuropathy is a well-described side-effect of BV therapy that is largely reversible (Siddiqi, Thomas, & Chen, 2014) . With a median 31Á3 months follow-up from the end of BV treatment, no new PN events were reported and 19 of the 30 patients (63%) who previously reported PN had resolution or improvement of all or some PN symptoms (Table I ). The median time to resolution or improvement was 3 weeks. At the end of follow-up, 25 patients (83Á3%) had no residual PN or Grade 1 PN, four patients had ongoing Grade 2 PN, and one patient had ongoing Grade 3 PN. The frequency and reversibility of PN in our present study are consistent with previous reports of BV therapy. In phase 2 and 3 trials of BV monotherapy for HL and anaplastic large-cell lymphoma, PN was reported in 53-67% of BV-treated patients (Pro et al., 2012; Younes et al., 2012; Moskowitz et al., 2015) , with 20% Grade 2 and 11% Grade 3 events reported in one study (Younes et al., 2012) , and 14% Grade 3 events in another study (Pro et al., 2012) . In those studies, complete resolution of PN was reported in 48-50% of patients (Pro et al., 2012; Younes et al., 2012) , and resolution or improvement was reported in 80-85% (Pro et al., 2012; Younes et al., 2012; Moskowitz et al., 2015) .
In conclusion, the combination of BV and bendamustine administered in the outpatient setting as first salvage therapy for relapsed or refractory HL produced a high ORR and CR rate, and 75% of patients were able to undergo ASCT. Crosswell, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, and Andres Forero-Torres contributed to the data and interpretation and critical review of the report; Neil Josephson contributed to the study design, data interpretation, and writing of the report; Yinghui Wang contributed to the study design, data interpretation, and critical review of the report. 136.07 (0.14-176.00) *Resolution is defined as event status of resolved/recovered or resolved/recovered with sequelae; or return to baseline or lower severity as of the latest assessment for pre-existing events. †For events that are not resolved, improvement is defined as decrease by at least one grade from worst grade as of the latest assessment. ‡Exclusive of patients with resolution of all events. (B) Progression-free survival (PFS) for all patients and those who underwent ASCT. (C) Duration of complete remission (CR) according to ASCT status. PFS was defined as the time from the first dose of combined therapy to disease progression/relapse or death from any cause. Duration of CR was defined as the time from first observation of CR to disease progression/relapse or death from any cause. The efficacy evaluable population included all patients who received at least two cycles of combined therapy and who had a baseline tumour assessment and at least one postbaseline tumour assessment before any new antitumour treatment, or who had documented disease progression at any time after the first dose of combined therapy and before any new antitumour treatment. 95% CIs were determined using a complementary log-log transformation method. Patients with no subsequent disease progression/relapse or death during the study were censored at the time of last on-study disease assessment demonstrating lack of progression/relapse. Patients who started a new antitumour treatment (excluding ASCT) were censored at the date of last disease assessment prior to initiation of the new treatment. ] 
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